智通财经APP讯，锦欣生殖(01951)公布，董事会决议建议采纳2025年股份计划(须待股东批准后，方可作实)，以令公司进一步将其董事及主要雇员的长远利益与公司利益保持一致，并激励彼等持续推动公司的增长及发展。2025年股份计划将根据上市规则第十七章构成一项透过发行新股份提供资金的股份计划。
于2025年9月25日，以2025年股份计划生效为条件，董事会决议(其中包括)： (i)根据2025年股份计划向管理层承授人授出合共137,235,000份购股权，其中有条件向董阳先生授出亦须待于股东特别大会上获独立股东有条件批准;及(ii)根据2025年股份计划向非执行承授人授出合共240万份购股权及120万股受限制股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.